Treatment with BIX01294, a G9a inhibitor, reduces αSMA expression in a model of unilateral ureteral obstruction in mice [62] and decreases the levels of myofibroblasts expressing αSMA in methylglyoxal‐treated mice [61]. The gene discussed is ACTA1; the disease is Ureteral obstruction.